Journal of Computational Biophysics and Chemistry · 1-20
The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.
VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery
Pea protein is gaining global attention as a sustainable, plant-based alternative to animal proteins due to its lower environmental impact. However, conventional thermal processing methods can degrade its functional and nutritional properties. This review explores sustainable non-thermal approaches for pea protein processing, focusing on pre-treatment, extraction, and modification. Ultrasonication is the most effective extraction technique and offers higher protein content (82.76 to 85.76%) compared to alkaline, air classification, and enzymatic methods. For protein modification, enzymatic treatment proves most effective, enhancing digestibility by 20.86 to 22.50% and solubility by 64.28 to 66.55%, while preserving structural integrity, compared to other non-thermal techniques. We critically assess the impact of these techniques on protein conformation, allergenicity reduction, and bioavailability and discuss their applications in food formulations and plant-based alternatives. Despite technological advances, significant research gaps remain in understanding molecular structural changes and challenges in industrial scalability. Future studies should focus on scaling processing methods.
pea proteinnon-thermal processingsonicationprotein extraction
The co-expression of epidermal growth factor receptor and carbonic anhydrase-IX in aggressive tumors such as triple-negative breast cancer contributes to therapeutic resistance through proliferative signaling and hypoxia-mediated adaptation. Dual inhibition of these targets represents a promising strategy for overcoming tumor resilience and enhancing treatment efficacy. A novel thiadiazole-based hybrid molecule ( N -(4-(( E )-1-((( Z )-5-acetyl-3-(4-sulfamoylphenyl)-1,3,4-thiadiazol-2(3 H )-ylidene)hydrazono)ethyl)phenyl)benzamide), ASTPB, was rationally designed through pharmacophore modeling, followed by molecular docking and molecular dynamics simulations for 200 ns to assess its dual-binding affinity to epidermal growth factor receptor and carbonic anhydrase-IX. Molecular dynamics simulations confirmed the stability of ASTPB complexes with both epidermal growth factor receptor and carbonic anhydrase-IX, as indicated by stable root mean square deviation values, consistent radius of gyration, and persistent hydrogen bonding, which supported its strong dual-binding affinity. Further quantum chemical analysis via density functional theory supported the electronic stability and reactive potential of ASTPB. In addition, in silico ADMET (Absorption, Distribution, Metabolism, Excretion, and toxicity) predictions indicated low toxicity, a wide safety margin, limited solubility and absorption, and overall favorable metabolic and distribution profiles. ASTPB was synthesized and exhibited potent dual inhibition of carbonic anhydrase-IX and epidermal growth factor receptor, with IC₅₀ values of 0.046 ± 0.007 µM and 0.059 ± 0.009 µM, respectively, comparable to standard inhibitors. In cytotoxicity assays, ASTPB was examined across several cancer cell lines (HePG-2, MCF-7, HCT-116, PC-3, MDA-MB-231), with the greatest efficacy against MDA-MB-231 (IC₅₀ = 18.15 µM) and minimal toxicity toward normal WI-38 cells (IC₅₀ = 72.46 µM). Cell cycle analysis revealed G0/G1 phase arrest, while Annexin V/PI staining indicated early apoptosis in 76.7% of cells. Molecular assays confirmed upregulation of Bax and caspase-3 (3.7-fold each) and downregulation of Bcl-2 (1.97-fold), indicating activation of the intrinsic apoptotic pathway. In conclusion, ASTPB is a promising dual carbonic anhydrase-IX/epidermal growth factor receptor inhibitor with selective cytotoxicity and potent pro-apoptotic activity, particularly in triple-negative breast cancer models. These findings support its potential as a multi-targeted therapeutic lead in the treatment of hypoxia-adapted, epidermal growth factor receptor–driven malignancies.
carbonic anhydrase IXepidermal growth factor receptortriple-negative breast cancerpharmacophore modeling
Journal of Computational Biophysics and Chemistry · مجلد 25 (11) · 2043-2063
Angiogenesis plays a pivotal role in tumor progression, and VEGFR-2 is a well-established therapeutic target in cancer treatment. In this study, we report the design, semi-synthesis, and comprehensive evaluation of a novel theobromine-based VEGFR-2 inhibitor, T-1-BHEPA [([Formula: see text]-[Formula: see text]-(4-(1-(2-benzoylhydrazono)ethyl)phenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1[Formula: see text]-purin-1-yl)acetamide]. A structure-based computer-aided drug design (CADD) approach was employed, beginning with pharmacophore modeling, followed by in-depth computational validation. The binding affinity of T-1-BHEPA to VEGFR-2 was examined through molecular docking, 400 ns molecular dynamics (MD) simulations, MM-GBSA binding energy calculations, and protein–ligand interaction fingerprinting (ProLIF) interaction analysis, all of which confirmed a strong and stable interaction with the VEGFR-2 active site. DFT calculations indicated T-1-BHEPA’s stability and reactivity. Before semi-synthesis, in silico ADMET evaluations highlighted good solubility, nonhepatotoxicity, low CYP2D6 interaction and noncarcinogenic potential, along with a favorable chronic toxicity profile. Consistent with these predictions, T-1-BHEPA exhibited potent in vitro VEGFR-2 inhibition (IC 50 [Formula: see text] 0.059 ± 0.006 [Formula: see text]M), comparable to sorafenib (IC 50 [Formula: see text] 0.045 ± 0.006 [Formula: see text]M). T-1-BHEPA demonstrated selective cytotoxicity against a panel of cancer cell lines, with pronounced activity against MDA-MB-231 (IC 50 [Formula: see text] 11.64 ± 1.0 [Formula: see text]M), and a high selectivity index (SI > 6.7) over normal WI-38 cells. Cell cycle analysis revealed G2/M phase arrest, while apoptosis assays confirmed significant increases in early and late apoptotic populations. These effects were further supported by molecular markers, including elevated caspase-3, upregulation of Bax and downregulation of Bcl-2, consistent with activation of the intrinsic apoptotic pathway. Overall, T-1-BHEPA represents a rationally designed and biologically validated VEGFR-2 inhibitor with promising anticancer efficacy and safety, warranting further preclinical development.
Lung inflammation is a hallmark of several respiratory diseases. Despite the great effectiveness of the synthetic antiinflammatory agents, they cause potential side effects. Polydatin (PD), a natural phytomedicine, has antioxidant and antiinflammatory effects. Its clinical applications are hindered due to poor aqueous solubility, low bioavailability, and rapid metabolism by first-pass effect. Herein, we report the development of a novel chitosan oligosaccharide-coated PD-loaded Poly dl-lactide-co-glycolide nanoparticles (COS-coated PD/PLGA NPs) against a bleomycin-induced pulmonary inflammation in a rat model. The NPs exhibited a small particle size of 188.57 ± 5.68 nm and a high zeta potential of + 18.13 ± 2.75 mV with spherical architecture and sustained release pattern of PD. In vivo studies in bleomycin-induced lung inflammation in a rat model revealed the superior prophylactic activity of COS-coated PD/PLGA NPs over the free drug (PD) as demonstrated by histopathological and immunohistochemical analyses, alongside biochemical assays evaluating oxidative stress biomarkers and inflammatory cytokine levels. Overall, the optimized COS-coated PD/PLGA NPs formulation offers a promising prophylactic platform against many respiratory diseases.
International Journal of Pharmaceutics X · مجلد 7 · 100232-100232
Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as a microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition to its hypoglycemic effect, VLD minimizes ocular inflammation and improves retinal blood flow for individuals with type 2 diabetes mellitus. Nevertheless, VLD can cause upper respiratory tract infections, diarrhea, nausea, hypoglycemia, and poor tolerability when taken orally regularly due to its high water solubility and permeability. Effective ocular administration of VLD is achieved using solid lipid nanoparticles (SLNPs), which improve corneal absorption, prolonged retention, and extended drug release. Ocuserts (OCUs) are sterile, long-acting ocular dosage forms that diminish the need for frequent dosing while improving residence time and stability. Therefore, this study intends to develop VLD solid lipid nanoparticle OCUs (VLD-SLNPs-OCUs) to circumvent the issues commonly associated with VLD. SLNPs were prepared using the double-emulsion/melt dispersion technique. The optimal formula has been implemented in OCUs. Optimization and development of VLD-SLNPs-OCUs were performed using a Box-Behnken Design (BBD). VLD-SLNPs-OCUs loading efficiency was 95.28 ± 2.87%, and differential scanning calorimetry data (DSC) showed the full transformation of VLD to an amorphous state and the excellent distribution in the prepared OCUs matrices. The in vivo release of VLD from the optimized OCUs after 24 h was 35.12 ± 2.47%, consistent with in vitro drug release data of 36.89 ± 3.11. The optimized OCUs are safe to use in the eye, as shown by the ocular irritation test. VLD-SLNPs-OCUs provide extended VLD release, an advantageous alternative to conventional oral dose forms, resulting in fewer systemic adverse effects and less variation in plasma drug levels. VLD-SLNPs-OCUs might benefit retinal microvascular blood flow beyond blood glucose control and may be considered a promising approach to treating diabetic retinopathy.
vildagliptinsolid lipid nanoparticlesOcusertocular drug delivery
Oral squamous cell carcinoma (OSCC) is a highly malignant and invasive tumor with significant mortality and morbidity. Current treatment modalities such as surgery, radiotherapy, and chemotherapy encounter significant limitations, such as poor targeting, systemic toxicity, and drug resistance. There is an urgent need for novel therapeutic strategies that offer targeted delivery, enhanced efficacy, and reduced side effects. The advent of lipid-based nanoparticles (LNPs) offers a promising tool for OSCC therapy, potentially overcoming the limitations of current therapeutic approaches. LNPs are composed of biodegradable and biocompatible lipids, which minimize the risk of toxicity and adverse effects. LNPs can encapsulate hydrophobic drugs, improving their solubility and stability in the biological environment, thereby enhancing their bioavailability. LNPs demonstrate significantly higher ability to encapsulate lipophilic drugs than other nanoparticle types. LNPs offer excellent storage stability, minimal drug leakage, and controlled drug release, making them highly effective nanoplatforms for the delivery of chemotherapeutic agents. Additionally, LNPs can be modified by complexing them with specific target ligands on their surface. This surface modification allows the active targeting of LNPs to the tumors in addition to the passive targeting mechanism. Furthermore, the PEGylation of LNPs improves their hydrophilicity and enhances their biological half-life by reducing clearance by the reticuloendothelial system. This review aims to discuss current treatment approaches and their limitations, as well as recent advancements in LNPs for better management of OSCC.
oral squamous cell carcinomalipid nanoparticlestargeted drug deliverychemotherapy
The rise of antibiotic resistance underscores the urgent need for novel antibacterial agents. DNA gyrase, an essential enzyme involved in bacterial DNA replication, is a promising target for antibacterial therapy. Computational approaches offer a cost-effective means to design and screen potential inhibitors, such as eugenol derivatives. This study aims to computationally design eugenol derivatives as potential antibacterial agents targeting DNA gyrase, assess their binding affinities, evaluate physicochemical properties, and toxicity, and select lead compounds for further investigation. Molecular docking simulations were conducted to investigate the binding affinities of eugenol derivatives and controls to DNA gyrase. Physicochemical properties and toxicity assessments of eugenol were evaluated. Lead compounds were selected based on drug likeness, toxicity, and binding affinity. Molecular docking studies revealed varying binding affinities of eugenol derivatives to DNA gyrase, with lead compounds exhibiting superior affinity compared to eugenol. Physicochemical properties indicated moderate lipophilicity and low aqueous solubility for eugenol. Toxicity assessment revealed mutagenicity and tumorigenicity. De novo compound synthesis generated 244 novel compounds, with 44 selected based on drug-likeness, toxicity, and binding affinity as lead candidates. These findings provide valuable insights for the development of novel antibacterial agents targeting DNA gyrase, with implications for combating antibiotic resistance.
International Journal of Pharmacology · مجلد 20 (1) · 62-71
Background and Objective: Alzheimer’s disease (AD) is a severe, diverse and complex brain disorder that slowly degrades cognitive and memory abilities. Patients with a history of long-term use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have a lower risk of AD, according to epidemiological research. The objective of the research was to synthesize a novel dipeptide prodrug of ibuprofen and evaluate its anti-Alzheimer’s potential. Materials and Methods: A Novel Ibuprofen compound (Ibu-GLVL) was synthesized by the catalyst microwave method. Characterization of the compound was done by IR, 1[H] NMR and mass spectroscopy. The anti-Alzheimer’s activity was investigated using the Rotarod test and Morris water test against aluminum chloride-induced neurodegeneration. Further, histopathology was done on the hippocampus isolated from the experimental animals. Results: The characterization analysis predicted the composition of the novel compound as ‘C’-66.27%, ‘H’-8.34%, ‘N’-7.73% and ‘O’-17.66%. The solubility studies indicated that the R2 value was 0.9816, the compound was stable in both the pH of gastric and intestine and the partition coefficient (log P) value was 1.64. Further, the synthetic compound reduced significantly (p<0.05) the aluminum chloride defects using the rotarod and Morris-water test, which was confirmed with the histopathological examination. In vitro studies predicted that the newly synthesized compound inhibited the acetylcholinesterase activity. Conclusion: The data suggested that the newly synthesized prodrug form of ibuprofen is stable and could possess the potential to reduce the complications of AD. More research in this direction might aid in the discovery of a new therapeutic agent that has the potential to manage the symptoms of AD.
Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents · مجلد 38 (7)
Background: Due to its low water solubility, Rutin, a crystalline medication used to treat a variety of conditions, has a limited rate of dissolution when given in gastrointestinal fluids. The present study planned to formulate and characterize Rutin using mesoporous silica material (SBA-15) as well as to determine the in-vitro dissolution properties. Methods: Rutin was formulated using mesoporous silica material such as SBA-15. Particle size distribution analysis, fourier transform-infrared (FT-IR) spectroscopy, scanning electron microscopy, and X-ray diffraction were used to characterize the compound in the complex. Rutins solubility and in-vitro release characteristics were assessed. Furthermore, the dissolution data (DD) Solver Excel add-in software was used to evaluate several mathematical models to interpret the Rutin dissolution kinetics from the mesoporous materials. Results: Differential scanning calorimetry was used to confirm Rutins amorphous state, which resulted in a significantly higher rate of dissolution than pure crystalline Rutin. The release of the drug from the Rutin/SBA-15 complex was well-simulated by the Weibull model. Notably, the SBA-15 carrier-mediated complex of Rutin exhibited the highest drug loading and dissolution rate, showing promising potential for enhancing Rutin bioavailability. Conclusion: The findings suggested that Rutin/SBA-15 could be easily incorporated into conventional oral pharmaceutical dosage forms such as capsules and therefore can be utilized for treating ailments such as allergies, inflammation, tumors, infections, protozoal diseases, and spasms. To assess the Rutin/SBA-15 complexs in-vivo pharmacokinetic performance and appropriateness for a range of pharmacological actions, more investigation is required.
Metal oxide-based adsorbents are quite in for wastewater treatment because of their selectivity, stable structure and very low solubility in aqueous systems. To explore the adsorption of methylene blue (MB), Mn 3 O 4 -Bi 2 O 3 adsorbents were made using a wet-impregnation technique with various concentrations of Mn 3 O 4 . The presence of Mn 3 O 4 contents on the surface of monoclinic Bi 2 O 3 was confirmed through representative scanning electron micrographs. The diffractions pertaining to cubic Mn 3 O 4 and monoclinic Bi 2 O 3 were noticed in the XRD pattern of 5% Mn 3 O 4 -Bi 2 O 3 which confirm the composite nature of the adsorbent. XPS analysis revealed the existance of Bi 4f, Bi 4d, Bi 4p, Bi4s, and Mn 2p core levels in Mn 3 O 4 -Bi 2 O 3 . The adsorption study divulged highest efficiency (∼95% and qe = ∼1.4 mgg -1 ) of 5% Mn 3 O 4 -Bi 2 O 3 composite among other contestants in removing 30 ppm MB at 28 ° C, pH 7 and 250 rpm. In addition to the determination of adsorption ability, the effect of preliminary dye concentration (5, 10, 20, and 30 ppm) and contact time (0.5–6 h) on the removal efficiency of prepared adsorbents were also monitored. The adsorption data from the batch experiments were evaluated using the Langmuir, Freundlich, Temkin, and Dubinin-Radushkevich-Kaganer (DRK) adsorption isotherms and pseudo 1 st and 2 nd -order kinetic models. The fitting of adsorption isotherms and kinetic models revealed the formation of adsorbate’s monolayer on the surface of adsorbents through the process of chemisorption. Through FTIR measurement, the MB adsorption onto the effective adsorbent (5% Mn 3 O 4 -Bi 2 O 3 ) was also confirmed. Moreover, TGA analysis showed ∼1.5% weight loss by 5% Mn 3 O 4 -Bi 2 O 3 before MB adsorption whereas ∼2.6% weight loss was noticed after dye adsorption onto the adsorbent. The antifungal activity was evaluated against the fungi A. solani and M. fructicola using the agar well diffusion technique. The 5% Mn 3 O 4 -Bi 2 O 3 composites have exceptional antifungal characteristics compared to Bi 2 O 3 and Mn 3 O 4 , with zone inhibition values of 58.6 and 53.9 mm, respectively.
methylene blue adsorptionmetal oxide adsorbentsdye removaladsorption isotherms
Quercetin (QtN) displays low systemic bioavailability caused by poor water solubility and instability. Consequently, it exerts limited anticancer action in vivo. One solution to increase the anticancer efficacy of QtN is the use of appropriate functionalized nanocarriers that preferentially target and deliver the drug to the tumor location. Herein, a direct advanced method was designed to develop water-soluble hyaluronic acid (HA)-QtN-conjugated silver nanoparticles (AgNPs). HA-QtN reduced silver nitrate (AgNO3) while acting as a stabilizing agent to produce AgNPs. Further, HA-QtN#AgNPs served as an anchor for folate/folic acid (FA) conjugated with polyethylene glycol (PEG). The resulting PEG-FA-HA-QtN#AgNPs (further abbreviated as PF/HA-QtN#AgNPs) were characterized both in vitro and ex vivo. Physical characterizations included UV-visible (UV-Vis) spectroscopy, Fourier transform infrared (FTIR) spectroscopy, transmission electron microscopy (TEM), particle size (PS) and zeta potential (ZP) measurements, and biopharmaceutical evaluations. The biopharmaceutical evaluations included analyses of the cytotoxic effects on the HeLa and Caco-2 cancer cell lines using the MTT assay; cellular drug intake into cancer cells using flow cytometry and confocal microscopy; and blood compatibility using an automatic hematology analyzer, a diode array spectrophotometer, and an enzyme-linked immunosorbent assay (ELISA). The prepared hybrid delivery nanosystem was hemocompatible and more oncocytotoxic than the free, pure QtN. Therefore, PF/HA-QtN#AgNPs represent a smart nano-based drug delivery system (NDDS) and could be a promising oncotherapeutic option if the data are validated in vivo.
International Journal of Food Properties · مجلد 26 (1) · 2294-2337
Honey, propolis, and passionflower contain a flavone known as chrysin. Researchers are studying chrysin to prove its potential to stop cancer cells growth. Chrysin cancer therapeutic potential is of great interest and numerous studies have been done to illustrate this potential. It is associated protein pathways effectively suppress tumor growth within the body. It is shown to have the ability to kill breast, prostate, lung, liver, and stomach cancerous cells. It can block Phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) and Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling in different animals against various cancers. Chrysin has the potential to kill breast cancer cells in a laboratory setting by inhibiting their cell division. Chrysin strongly suppresses Matrix metalloproteinase-9 (MMP-9), Urokinase plasminogen activator (uPA) and Vascular endothelial growth factor (VEGF), i.e. factors that can cause cancer. Chrysin has the ability to suppress the androgen receptor (AR), a protein necessary for prostate cancer development and metastasis. It starts the caspase cascade and blocks protein synthesis to kill lung cancer cells. Unnecessary apoptosis can be prevented by stopping certain protein pathways. Chrysin significantly decreased lung cancer metastasis in various animal-modeled studies. Chrysin induces apoptosis and stops colon cancer cells in the G2/M cell cycle phase. Chrysin suppresses colon cancer-promoting cyclin B1 and cyclin-dependent kinase 2. Chrysin suppressed cyclin B1 and CDK2 production in order to stop cancerous growth. Chrysin prevents tumor growth and cancer spread by blocking blood vessel expansion. Chrysin’s solubility, accessibility and bioavailability may limit its medical use. Chrysin targets numerous cancer-related communication pathways present in cells. Chrysin may reduce the chances of the onset of cancer, it can also serve as an alternative treatment as a whole to prevent and treat various cancers, but more clinical trials and research studies are needed to fully unlock its potential.
Gefitinib (GFT) is a tyrosine kinase inhibitor drug used as a first-line treatment for patients with advanced or metastatic non-small cell lung, colon, and breast cancer. GFT exhibits low solubility and hence low oral bioavailability, which restricts its clinical application. One of the most important trends in overcoming such problems is the use of a vesicular system. Cubosomes are considered one of the most important vesicular systems used to improve solubility and oral bioavailability. In this study, GFT cubosomal nanoparticles (GFT-CNPs) were prepared by the emulsification method. The selected formulation variables were analyzed and optimized by full factorial design and response surface methodology. Drug entrapment efficiency (EE%), transmission electron microscopy, particle size, polydispersity index, in vitro release and its kinetics, and the effect of storage studies were estimated. The chosen GFT-CNPs were subjected to further investigations as gene expression levels of tissue inhibitors of metalloproteinases-1 (TIMP-1) and matrix metalloproteinases-7 (MMP-7), colon biomarkers, and histopathological examination of colon tissues. The prepared GFT-CNPs were semi-cubic in shape, with high EE%, smaller vesicle size, and higher zeta potential values. The in vivo data showed a significant decrease in the serum level of embryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and gene expression level of TIMP-1 and MMP-7. Histopathological examination showed enhancement in cancer tissue and highly decreased focal infiltration in the lamina propria after treatment with GFT-CNPs.